Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

BACKGROUND: Sunitinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant/intolerant gastrointestinal stromal tumors (GIST). METHODS: A meta-analysis of 10 prospective clinical studies in advanced RCC and GIST was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Khosravan, Reza, Motzer, Robert J., Fumagalli, Elena, Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526090/
https://www.ncbi.nlm.nih.gov/pubmed/27154065
http://dx.doi.org/10.1007/s40262-016-0404-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526090/
https://www.ncbi.nlm.nih.gov/pubmed/27154065
http://dx.doi.org/10.1007/s40262-016-0404-5

Ejemplares similares